P Barrow1, M Khan, F Lalloo, D G Evans, J Hill. 1. Department of Colorectal Surgery, Manchester Royal Infirmary, Central Manchester University Hospitals NHS Foundation Trust.
Abstract
BACKGROUND: The British Society of Gastroenterology recommends that all familial adenomatous polyposis (FAP) and Lynch syndrome (LS) families are screened in the context of a registry. This systematic review was performed to appraise the published evidence for registration and screening in relation to colorectal cancer (CRC) incidence and mortality. METHODS: Five electronic databases were searched using a combination of medical subject heading terms and free-text keywords. Titles and abstracts were scrutinized by two independent reviewers. Inclusion criteria were English-language studies describing CRC incidence and/or mortality in patients with FAP or LS, with comparison of either: screened and unscreened patients, or time periods before and after establishment of the registry. RESULTS: Of 4668 abstracts identified, 185 full-text articles were selected; 43 studies fulfilled the inclusion criteria. No randomized clinical trial evidence was identified. For FAP, 33 of 33 studies described a significant reduction of CRC incidence and mortality with registration and screening. For LS, nine of ten studies described a reduction of CRC incidence and mortality with registration and screening. Five studies (FAP, 2; LS, 3) provided evidence for complete prevention of CRC-related deaths during surveillance. Clinical and statistical heterogeneity prevented pooling of data for meta-analysis. CONCLUSION: Studies consistently report that registration and screening result in a reduction of CRC incidence and mortality in patients with FAP and LS (level 2a evidence, grade B recommendation). Funding and managerial support for hereditary CRC registries should be made available.
BACKGROUND: The British Society of Gastroenterology recommends that all familial adenomatous polyposis (FAP) and Lynch syndrome (LS) families are screened in the context of a registry. This systematic review was performed to appraise the published evidence for registration and screening in relation to colorectal cancer (CRC) incidence and mortality. METHODS: Five electronic databases were searched using a combination of medical subject heading terms and free-text keywords. Titles and abstracts were scrutinized by two independent reviewers. Inclusion criteria were English-language studies describing CRC incidence and/or mortality in patients with FAP or LS, with comparison of either: screened and unscreened patients, or time periods before and after establishment of the registry. RESULTS: Of 4668 abstracts identified, 185 full-text articles were selected; 43 studies fulfilled the inclusion criteria. No randomized clinical trial evidence was identified. For FAP, 33 of 33 studies described a significant reduction of CRC incidence and mortality with registration and screening. For LS, nine of ten studies described a reduction of CRC incidence and mortality with registration and screening. Five studies (FAP, 2; LS, 3) provided evidence for complete prevention of CRC-related deaths during surveillance. Clinical and statistical heterogeneity prevented pooling of data for meta-analysis. CONCLUSION: Studies consistently report that registration and screening result in a reduction of CRC incidence and mortality in patients with FAP and LS (level 2a evidence, grade B recommendation). Funding and managerial support for hereditary CRC registries should be made available.
Authors: Daniel Herzig; Karin Hardiman; Martin Weiser; Nancy You; Ian Paquette; Daniel L Feingold; Scott R Steele Journal: Dis Colon Rectum Date: 2017-09 Impact factor: 4.585
Authors: Sung Min Jung; Yong Sik Yoon; Seok-Byeong Lim; Chang Sik Yu; Jin Cheon Kim Journal: World J Gastroenterol Date: 2016-05-07 Impact factor: 5.742
Authors: Elizabeth V Clarke; Kristin R Muessig; Jamilyn Zepp; Jessica E Hunter; Sapna Syngal; Louise S Acheson; Georgia L Wiesner; Susan K Peterson; Kellene M Bergen; Elizabeth Shuster; James V Davis; Jennifer L Schneider; Tia L Kauffman; Marian J Gilmore; Jacob A Reiss; Alan F Rope; Jennifer E Cook; Katrina A B Goddard Journal: Fam Cancer Date: 2019-07 Impact factor: 2.375